Form 4: Bicycle Therapeutics CEO Sells Shares to Cover Tax Obligations

Bicycle Therapeutics PLC's CEO, Kevin Lee, sold 5,461 ordinary shares across two transactions in early July 2025, solely to satisfy statutory tax withholding obligations related to restricted stock unit vesting.

Summary

• Kevin Lee, Chief Executive Officer and Director of Bicycle Therapeutics PLC, engaged in two non-discretionary sales of ordinary shares.
• On July 2, 2025, 2,268 shares were sold at a weighted average price of $7.09 per share, with prices ranging from $7.09 to $7.14.
• On July 3, 2025, an additional 3,193 shares were sold at a weighted average price of $7.44 per share, with prices ranging from $7.405 to $7.483.
• These sales were mandated "sell to cover" transactions to fund minimum statutory tax withholding obligations associated with the vesting and settlement of restricted stock units, and do not represent discretionary sales by the Reporting Person.
• Following these transactions, Kevin Lee directly beneficially owns 480,804 ordinary shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's a sale by an insider, the explicit explanation that it's a non-discretionary 'sell to cover' for tax obligations mitigates any negative interpretation typically associated with insider selling. It's a routine event related to executive compensation.

Negatives

• Sale of 5,461 ordinary shares by a key executive (CEO) over two days.
• Reduction in the CEO's direct beneficial ownership from 483,997 to 480,804 shares after the transactions.

Future Outlook

NA

Management Comments

• The sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary sale by the Reporting Person.

Industry Context

This Form 4 filing reflects a routine executive compensation event, specifically the sale of shares to cover tax obligations upon the vesting of restricted stock units. Such 'sell to cover' transactions are common across industries when executives receive equity compensation and are generally not indicative of a change in management's confidence in the company's prospects, unlike discretionary insider sales.

Stakeholder Impact

• Shareholders: The sale is non-discretionary and for tax purposes, so it should not be interpreted as a lack of confidence by the CEO. The impact on share price should be minimal, as it's a routine event.

Key Dates

Recommendation

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Trading, Share Sale, Executive Compensation, Restricted Stock Units, Tax Withholding, Kevin Lee